Drug Shortages May Leave Millions Without Access to Weight-Loss Medications

In a significant move to address the global obesity epidemic, the World Health Organization (WHO) has released its first official guidance on the use of GLP-1 medications for obesity treatment. The guidelines, published on December 1, come as obesity affects more than one billion people worldwide and is associated with 3.7 million deaths annually.

GLP-1 drugs, which mimic the natural hormone glucagon-like peptide-1, have gained prominence for treating type 2 diabetes and promoting weight loss. While these medications were added to the WHO’s Essential Medicines List for diabetes management in September 2025, the new guidelines specifically extend their recommended use to obesity treatment.

The WHO has issued two key conditional recommendations regarding GLP-1 therapies for obesity. First, these medications “may be used by adults, but excluding pregnant women, for the long-term treatment of obesity.” The conditional nature of this recommendation stems from limited data on long-term safety and efficacy, as well as concerns about cost and healthcare system readiness.

Second, the WHO recommends that patients prescribed GLP-1 therapies should also receive “intensive behavioral interventions,” including healthy diet guidance, physical activity programs, and professional healthcare support as part of a comprehensive treatment approach.

“Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms.”

The economic impact of obesity is substantial, with global costs projected to reach $3 trillion annually by 2030. Beyond the direct health consequences, obesity is a major driver of cardiovascular disease, type 2 diabetes, and certain cancers, placing enormous strain on healthcare systems worldwide.

The WHO’s guidelines highlight serious concerns about equitable access to these medications. Despite rapid expansion in GLP-1 production, these therapies are predicted to reach less than 10% of potential beneficiaries by 2030. The organization warns that without deliberate policies, access to these treatments could exacerbate existing health disparities.

“WHO calls for urgent action on manufacturing, affordability and system readiness to meet global needs,” the agency stated. The guidelines specifically encourage strategies like pooled procurement, tiered pricing, and voluntary licensing arrangements to expand access globally.

The obesity crisis shows no signs of abating, with global prevalence expected to double by 2030. The WHO emphasizes that GLP-1 medications represent just one component of a multi-faceted approach needed to combat obesity. Creating healthier environments that promote wellness, implementing early interventions for high-risk individuals, and ensuring lifelong healthcare access remain critical pillars of an effective obesity strategy.

These new guidelines reflect the WHO’s recognition of obesity as a complex chronic disease requiring long-term management rather than short-term fixes. By formally acknowledging the role of pharmaceutical interventions alongside behavioral approaches, the WHO has signaled a significant shift in global obesity treatment protocols.

As these medications become increasingly prominent in obesity management, questions about their long-term effectiveness, safety profiles, and appropriate use will likely drive further research and policy development. Meanwhile, healthcare systems worldwide face the challenge of incorporating these recommendations while addressing the substantial cost and access barriers that currently limit their widespread adoption.